HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keystone, E Search for Related Content PubMed PubMed Citation Articles by Keystone, E

Treatments no longer in development for rheumatoid arthritis

The Centre for Advanced Therapeutics, Mount Sinai Hospital and University of Toronto, Canada

Correspondence to:
Correspondence to:
Dr E Keystone, Mount Sinai Hospital, Room 1005, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5;
edkeystone@mtsinai.on.ca

Keywords: rheumatoid arthritis; T cells

Abbreviations: RA, rheumatoid arthritis; RCT, randomised controlled trial; MMP, matrix metalloproteinase

The first 150 words of the full text of this article appear below.

T CELLS AS THERAPEUTIC TARGETS
Much of our experience with biological agents in autoimmune disease has been derived from studies of T cell directed therapy in rheumatoid arthritis (RA) (box 1). Data from these studies have provided substantial insight into study design, product development, and T cell biology. Initial studies entailed targeting of CD4 T cells with murine monoclonal antibodies (mAb) of differing isotypes directed at a variety of epitopes on the CD4 molecule. Between 1989–1994, eight short-term open label trials yielded promising results with clinical responses in 60%–75% of patients (reviewed in Strand and Keystone¹). In 1996, seven years after the initial studies were published, the first randomised placebo controlled trial (RCT) of murine anti-CD4 mAb showing no clinical benefit was reported.² A similar discrepancy in clinical outcome between early uncontrolled trials and placebo RCTs was also observed with a murine anti-CD5 immunotoxin conjugate,³ as well as the chimeric anti-CD4 mAb, cM412.^4,5 . . . [Full text of this article]

This article has been cited by other articles:

				G. C. Pinheiro, M. A. Scheinberg, M. Aparecida da Silva, and S. Maciel Anti-Cyclic Citrullinated Peptide Antibodies in Advanced Rheumatoid Arthritis Ann Intern Med, August 5, 2003; 139(3): 234 - 235. [Full Text] [PDF]